{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:12:10Z","timestamp":1783357930486,"version":"3.54.6"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"Importance<\/jats:title>Chronic prurigo (CPG), including prurigo nodularis, is a difficult disease to treat and considerably affects patients\u2019 quality of life. Helping patients obtain control of CPG is a major treatment goal.<\/jats:p><\/jats:sec>Objective<\/jats:title>To develop and validate the Prurigo Control Test (PCT), a tool for assessing disease control in CPG, and to identify a cutoff value for controlled disease to aid treatment decisions.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This qualitative study followed the current recommendations for patient-reported outcome measure development in the generation and validation of the PCT. The final PCT was obtained after item generation, followed by reduction and selection, and was then tested for internal consistency and test-retest reliability, convergent validity, known-group validity, screening accuracy, and banding. The item-generation phase resulted in an unselected list of 69 potential PCT items. Impact analysis, interitem correlation, and review for content (face) validity resulted in final set of 5 PCT items. The validation study was performed among patients across 2 expert centers in Germany. Data were analyzed from February 2017 to November 2019.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>A 5-item PCT with a recall period of 2 weeks was developed. A cutoff value of 10 points or higher was determined as suitable for identifying patients with well-controlled vs poorly controlled CPG.<\/jats:p><\/jats:sec>Results<\/jats:title>Of the 95 patients included in the validation study, the median (range) age was 63 (19-87) years, 50 patients (53%) were women, and the median (range) disease duration was 72 (9-774) months. The validation study yielded good internal consistency reliability (Cronbach \u03b1, 0.86) and a high degree of convergent validity. The PCT demonstrated good known-group validity and could discriminate between patients who differed in prurigo control. Test-retest reliability was high, and the intraclass correlation coefficient was 0.94, indicating excellent reproducibility.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This qualitative study showed that the PCT is able to assess disease control in patients with CPG. Its retrospective approach, brevity, and simple scoring likely make the PCT suitable for clinical practice and trials.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.5519","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T17:47:25Z","timestamp":1705513645000},"page":"187","source":"Crossref","is-referenced-by-count":12,"title":["Development and Validation of a Patient-Reported Outcome Measure to Assess Disease Control in Chronic Prurigo"],"prefix":"10.1001","volume":"160","author":[{"given":"Martin","family":"Metz","sequence":"first","affiliation":[{"name":"Institute of Allergology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"},{"name":"Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Zeidler","sequence":"additional","affiliation":[{"name":"Center for Chronic Pruritus, Department of Dermatology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Hawro","sequence":"additional","affiliation":[{"name":"Institute and Comprehensive Centre for Inflammation Medicine, Department of Dermatology, Allergology and Venereology, University Medical Center Schleswig-Holstein, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Pereira","sequence":"additional","affiliation":[{"name":"Institute of Allergology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"},{"name":"Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Maurer","sequence":"additional","affiliation":[{"name":"Institute of Allergology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"},{"name":"Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Bonnekoh","sequence":"additional","affiliation":[{"name":"Institute of Allergology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"},{"name":"Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Krause","sequence":"additional","affiliation":[{"name":"Institute of Allergology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pritchard","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[{"name":"Center for Chronic Pruritus, Department of Dermatology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Weller","sequence":"additional","affiliation":[{"name":"Institute of Allergology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"doi230068r1","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/jdv.2018.32.issue-7","article-title":"European Academy of Dermatology and Venereology European Prurigo Project: expert consensus on the definition, classification and terminology of chronic prurigo.","volume":"32","author":"Pereira","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"doi230068r2","doi-asserted-by":"publisher","DOI":"10.1097\/itx.0000000000000042","article-title":"IFSI-guideline on chronic prurigo including prurigo nodularis.","volume":"5","author":"St\u00e4nder","year":"2020","journal-title":"Itch (Phila)"},{"issue":"3","key":"doi230068r3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jaad.2020.08.035","article-title":"The characteristics and impact of pruritus in adult dermatology patients: a prospective, cross-sectional study.","volume":"84","author":"Hawro","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi230068r4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/jdv.2019.33.issue-1","article-title":"The self-assessed psychological comorbidities of prurigo in European patients: a multicentre study in 13 countries.","volume":"33","author":"Brenaut","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"doi230068r5","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3701","article-title":"Investigator\u2019s Global Assessment of chronic prurigo: a new instrument for use in clinical trials.","volume":"101","author":"Zeidler","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"doi230068r6","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1111\/jdv.2018.32.issue-10","article-title":"Prurigo Activity Score (PAS): validity and reliability of a new instrument to monitor chronic prurigo.","volume":"32","author":"P\u00f6lking","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"doi230068r7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis.","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"doi230068r8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00403-020-02148-0","article-title":"The impact of prurigo nodularis on quality of life: a systematic review and meta-analysis.","volume":"313","author":"Janmohamed","year":"2021","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"doi230068r9","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1111\/jdv.v34.10","article-title":"Chronic nodular prurigo: clinical profile and burden: a European cross-sectional study.","volume":"34","author":"Pereira","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"doi230068r10","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3471","article-title":"Treatment and burden of disease in a cohort of patients with prurigo nodularis: a survey-based study.","volume":"100","author":"Todberg","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"doi230068r11","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jaci.2013.12.1076","article-title":"Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control.","volume":"133","author":"Weller","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"doi230068r12","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.jaip.2020.02.038","article-title":"Validation of the Angioedema Control Test (AECT)\u2014a patient-reported outcome instrument for assessing angioedema control.","volume":"8","author":"Weller","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"doi230068r13","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/all.v75.5","article-title":"Development of the Angioedema Control Test\u2014a patient-reported outcome measure that assesses disease control in patients with recurrent angioedema.","volume":"75","author":"Weller","year":"2020","journal-title":"Allergy"},{"key":"doi230068r14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-4-79","article-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.","volume":"4","author":"U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"doi230068r15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: a survey for assessing asthma control.","volume":"113","author":"Nathan","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"doi230068r16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/ced.1994.19.issue-3","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"doi230068r17","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0895-4356(98)00109-7","article-title":"Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project.","volume":"51","author":"Gandek","year":"1998","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"doi230068r18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jaad.2008.04.006","article-title":"A pilot quality-of-life instrument for pruritus.","volume":"59","author":"Desai","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi230068r19","doi-asserted-by":"publisher","first-page":"562","DOI":"10.2340\/00015555-1544","article-title":"German version of ItchyQoL: validation and initial clinical findings.","volume":"93","author":"Krause","year":"2013","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"doi230068r20","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.jaci.2017.04.050","article-title":"Responsiveness and minimal important difference of the urticaria control test.","volume":"140","author":"Ohanyan","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"doi230068r21","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"doi230068r22","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/jdv.v35.3","article-title":"The burden in chronic prurigo: patients with chronic prurigo suffer more than patients with chronic pruritus on non-lesional skin: a comparative, retrospective, explorative statistical analysis of 4,484 patients in a real-world cohort.","volume":"35","author":"Zeidler","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"doi230068r23","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3726","article-title":"Chronic nodular prurigo: a European cross-sectional study of patient perspectives on therapeutic goals and satisfaction.","volume":"101","author":"Pereira","year":"2021","journal-title":"Acta Derm Venereol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2814079\/jamadermatology_metz_2024_oi_230068_1707346926.96871.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T16:01:57Z","timestamp":1708531317000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2814079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.5519","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}